Fig. 1.

Dasatinib impairs proliferation, but not colony formation and differentiation of human CB CD34⁺ progenitor cells. Cord blood CD34⁺ cells (3 × 10⁴) were plated in T25 flask precoated with MS5 stromal cells. Cells were expanded in LTC medium with dasatinib added weekly as indicated. Cultures were demi-depopulated weekly for counting and CFC assay. a Representative figure of weekly cumulative cell counts is shown. b Percentages of cell growth as compared to the control group (% growth of control) on stroma by adding dasatinib are shown as mean value from three independent coculture experiments. c The total number of CFCs generated per T25 flask was calculated by the number of CFCs/10⁴ plated cells multiplied by the cell counts weekly. Percentages of colonies as compared to the control group (% colonies of control) after dasatinib treatment are shown. Data were from three independent coculture experiments. d Cells (10⁴) in suspension were plated at weeks 2 and 3 for CFC assay. Percentages of colonies as compared to the control group (% colonies of control) after dasatinib treatment are shown. e One thousand freshly isolated CB CD34⁺ cells were analyzed for CFC assay. Percentages of colonies as compared to the control group (% colonies of control) after dasatinib treatment are shown. Data were from three independent experiments. f The myeloid differentiation of cells in suspension from the coculture system was monitored by FACS with antibodies against CD11b, CD14, and CD15 at weeks 2 and 4. Representative figures out of three independent experiments are shown. Columns, means of three independent experiments; bars, SE (**p < 0.05)